Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Latest pharma news update

Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company’s mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases.

The tender offer for all of the outstanding shares of Translate Bio common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, September 13, 2021. The minimum tender condition and all of the other conditions to the offer have been satisfied and on September 14, 2021, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Translate Bio through the merger of a wholly owned subsidiary of Sanofi with and into Translate Bio, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Translate Bio continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

In connection with the merger, all Translate Bio shares not validly tendered in the tender offer have been converted into the right to receive the same $38 per share in cash, without interest thereon and net of any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of September 14, 2021, Translate Bio common stock will cease to be traded on the NASDAQ Global Select Stock Market.

Morgan Stanley & Co. International plc acted as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP acted as legal counsel. Centerview Partners acted as lead financial advisor to Translate Bio in the transaction, while Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal counsel. Evercore also acted as a financial advisor in this transaction to Translate Bio. MTS Health Partners, LP also gave financial advice to Translate Bio.

Tags : #Sanofi #TranslateBio #MrnaVaccine

About the Author


Team Medicircle

Related Stories

12 Nov

Sanofi completes acquisition of Kadmon

Latest pharma news updates

View
20 Sep

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Latest pharma news update

View
16 Sep

Everest Medicines enters into agreement with Providence Therapeutics to advance mRNA vaccines and Therapies

Latest Pharma News Update

View
05 Aug

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics

Corporate Pharma news upedat

View
17 Jul

LabGenius announces research collaboration with Ablynx, a Sanofi Company

Latest pharma update : Research and Collaboration

View
16 Jul

Sanofi extends collaboration with Genedata for Pharmaceutical Development & Manufacturing Science

Latest FDA approvals update

View
14 Jul

Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma

As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers.

View
09 Jul

Sanofi, GSK get approval for Phase 3 COVID-19 vaccine trial in India

In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus strain (D.614), while a second stage will evaluate a second formulation targeting the Beta variant (B.1.351)

View
03 Jul

Germany issues world's strongest recommendation for mixing Covid-19 vaccines

Mixing vaccines are safe says Germany

View
26 Jun

Country soon to get world’s first DNA-plasmid vaccine by Zydus Cadilla: Chairman COVID-19 NTAGI

Zydus Cadila vaccine to be available by September

View

-Advertisements-




Trending Now

Wellbeing Nutrition Kicks Off 2025 with the Bold “Unhustle Fitness” Campaign; Urging 1 Billion Indians to Rethink Fitness and Prioritise Recovery as StrengthJanuary 10, 2025
Dr. Vijay Kumar Datla Foundation Opens BE Skill Development CentreJanuary 10, 2025
Healthcare Sector Industry Seeks Transformative Union Budget: Experts expects Govt. to January 09, 2025
Vaccines, Screenings, and Hope: Leading the Way to a Cancer-Free FutureJanuary 09, 2025
Does Intelligence Determine Motherhood? Bombay High Court Challenges Social StigmaJanuary 09, 2025
The End of Needles: How IIT Bombay’s Shock Syringe Could Transform MedicineJanuary 09, 2025
International Conference on Gender and Technology from January 16January 09, 2025
8 Ways A Deviated Septum Can Impact People's LifestyleJanuary 09, 2025
Pre-Budget 2025-26 expectations for healthcare industryJanuary 09, 2025
Understanding Angina: A Comprehensive OverviewJanuary 08, 2025
Sick of Waiting: Bold Budget Moves That Could Save Indian HealthcareJanuary 08, 2025
Where Science Meets Smiles: Robotic Rehab Giving Hope to Kids with Mobility ChallengesJanuary 08, 2025
Can Technology Be Racist? FDA Says Yes, Unveils New Pulse Oximeter GuidelinesJanuary 08, 2025
Medanta strengthens its Renal Care Institute: Appoints leading urologist Dr. Sanjay Gogoi as ChairmanJanuary 08, 2025
CARE Hospitals, Performs India’s First Bone Grafting Procedure Using Advanced Synthes RIA2 SystemJanuary 07, 2025
quotes on HMPVJanuary 07, 2025
Orbit Startups and Sanabil Investments Launch Accelerator for Early-Stage Tech Innovation Across Saudi Arabia and MENAJanuary 07, 2025
Montra Electric, Murugappa Group`s Flagship EV brand, set to redefine Mid to Last mile urban Cargo solutions with the launch of Electric Small Commercial vehicle (e-SCV) and Electric 3W Super Cargo at Bharat Mobility Global Expo 2025January 07, 2025
Çelebi Delhi Cargo Terminal Celebrates 15 Glorious Years of Excellence at AAROHAN ‘24January 07, 2025
RNT Health Insights Receives Second US FDA Breakthrough Device Designation for Esophageal Cancer Detection ToolJanuary 07, 2025